VivoSim Labs to Add Rat Liver Model to NAMkind Platform
New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans SAN DIEGO, Sept.
01, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (Nasdaq: VIVS) (the
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.